期刊文献+

阿托伐他汀的药物基因组学研究进展 被引量:8

Advances in search for pharmacogenomics of atorvastatin
下载PDF
导出
摘要 阿托伐他汀是目前临床上广泛使用的口服降脂药,其对冠心病的一级和二级预防具有重要作用;但其疗效以及不良反应存在显著的个体差异,这与药物相关基因的多态性有关。本文主要介绍了基因多态性在阿托伐他汀的代谢、转运以及不良反应等方面的作用。 Atorvastatin is widely used as an oral lipid-lowering drug and it has an important role in the prevention of coronary heart disease.However,wide interindividual variations exist in the plasma lipid response to statin treatment including atorvastatin,which may due to drug-related gene polymorphism.This review states the effect of gene polymorphism on the aspect of metabolism,transportation,receptor,and adverse effect based on literature and cases in recent years,which can help provide reference for individualized treatment.
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2011年第11期888-891,共4页 The Chinese Journal of Clinical Pharmacology
基金 广东省科技计划基金资助项目(2009B080701105)
关键词 阿托伐他汀 基因多态性 药物基因组学 atorvastatin genetic polymorphism pharmacogenomics
  • 相关文献

参考文献26

  • 1Park JE, Kim KB, Bae SK, et al. Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin [ J]. Xenobiotica, 2008 ; 38 : 1240 - 1251.
  • 2Sim SC. Home page of the human cytochrome P450 (CYP) allele nomenclature committee[EB/OL], http://www, cypalleles, ki. se/, 2008 - 09 - 09.
  • 3Kajinami K, Brousseau ME, Ordovas JM, et al. CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvas- tatin in primary hypercholesterolemia [ J ]. Am J Cardiol, 2004 ; 93 : 104 - 107.
  • 4Becker ML, Visser LE, van Schaik RH, et al. Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching dur- ing simvastatin and atorvastatin therapy [ J ]. Pharmacoepidemiol Drug Saf, 2010; 19:75 -81.
  • 5Gao Y, Zhang LR, Fu Q. CYP3A4 * 1G polymorphism is associat- ed with lipid - lowering efficacy of atorvastatin but not of simvastatin [J]. Eur J Clin Pharmacol, 2008; 64:877-882.
  • 6Wang D, Guo Y, Wrighton SA, et al. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs [ J]. Pharmacogenomics J, 2011 ; 11:274 - 286.
  • 7Kivisto KT, Niemi M, Schaeffeler E, et al. Lipid - lowering re- sponse to statins is affected by CYI~A5 polymorphism [ J~. Phar- macogenetics, 2004 ; 14 : 523 - 525.
  • 8Wilke RA, Moore JH, Burmester JK. Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin - induced muscle damage [ J ]. Pharmacogenet Genomics, 2005 ; 15:415 -421.
  • 9Kameyama Y, Yamashita K, Kobayashi K, et al. Functional char- acterization of SLCO1 B1 ( OATP - C) variants, SLCOI BI * 5, SL- CO1B1 * 15 and SLCO1B1 * 15 + CIO07G, by using transient ex- pression systems of HeLa and HEK293 cells [ J ]. Pharmacogenet Genomics, 2005; 15:513-522.
  • 10Pasanen MK, Fredrikson H, Neuvonen PJ, et al. Different effects of SLCO1B1 polymorphism on the pharmaeokineties of atorvastatin and rosuvastatin [ J]. Clin Pharmacol Ther, 2007; 82:726 -733.

同被引文献87

引证文献8

二级引证文献65

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部